Medannex
Private Company
Funding information not available
Overview
Medannex is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach to treating cancer and autoimmune diseases by targeting the protein annexin-A1. Its lead candidate, MDX-124, is a first-in-class monoclonal antibody undergoing a Phase 1b study in oncology, with preparations underway for studies in autoimmune indications. The company leverages strong academic collaborations and is led by a seasoned team with significant biotech experience, positioning itself to address significant unmet medical needs in multiple therapeutic areas.
Technology Platform
Platform focused on inhibiting annexin-A1 (ANXA1), a protein that drives cancer progression and autoimmune disease pathogenesis, using a first-in-class monoclonal antibody (MDX-124).
Opportunities
Risk Factors
Competitive Landscape
Medannex appears to be a pioneer with the only therapeutic monoclonal antibody targeting annexin-A1 in clinical development, giving it a first-mover advantage. Competition is indirect, coming from other oncology immunotherapies and autoimmune disease biologics with different mechanisms. Validation of the target could rapidly alter the competitive landscape.